Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 52-week open label, long-term safety extension study of CAM2038 in patients with chronic non-cancer pain

Next Previous
Trial Profile

A 52-week open label, long-term safety extension study of CAM2038 in patients with chronic non-cancer pain

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 16 May 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Buprenorphine (Primary)
  • Indications Pain
  • Focus Therapeutic Use

    • Most Recent Events

    • 09 May 2019 According to a Camurus media release, the last patients has completed their treatment during the first quarter of 2019. After closing of the database and compiling the results from this study , the company will meet with European regulatory authorities to discuss the regulatory submission for CAM2038 for the treatment of chronic pain. The company plan to submit in the EU during the first half of 2020.
    • 09 May 2019 Status changed from recruiting to active, no longer recruiting, according to a Camurus media release.
    • 05 Feb 2019 According to a Camurus media release, long-term safety results are expected in the second quarter 2019.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top